Literature DB >> 33970024

Psychotropic Polypharmacy Among Children and Youth with Autism: A Systematic Review.

Chantel Ritter1, Katherine Hewitt2,3, Carly A McMorris2,3.   

Abstract

Objectives: Majority of youth with autism are taking two or more medications (psychotropic or nonpsychotropic) simultaneously, also known as polypharmacy. Yet the efficacy and the potential outcomes of polypharmacy in this population are widely unknown. This systematic literature review described the trends of polypharmacy among autistic youth, and identified factors associated with polypharmacy.
Methods: Sixteen studies were included, encompassing over 300,000 youth with autism.
Results: Rates of polypharmacy varied quite substantially across studies, ranging from 6.8% to 87% of autistic youth. Having psychiatric comorbidities, self-injurious behaviors, and physical aggression, as well as being male and older, were associated with higher rates of polypharmacy.
Conclusion: Findings emphasize the importance of further research to determine appropriate practices related to the monitoring of adverse side effects, and the long-term impact of polypharmacy among autistic youth.

Entities:  

Keywords:  autism; children; mental health; multiple medications; polypharmacy; psychotropic medications; youth

Year:  2021        PMID: 33970024     DOI: 10.1089/cap.2020.0110

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  2 in total

Review 1.  Dynamic and Systemic Perspective in Autism Spectrum Disorders: A Change of Gaze in Research Opens to A New Landscape of Needs and Solutions.

Authors:  Cristina Panisi; Marina Marini
Journal:  Brain Sci       Date:  2022-02-11

2.  A Retrospective Chart Review of Factors Impacting Psychotropic Prescribing Patterns and Polypharmacy Rates in Youth with Autism Spectrum Disorder during the COVID-19 Pandemic.

Authors:  Evan Taniguchi; Kerry Conant; Kylie Keller; Soo-Jeong Kim
Journal:  J Clin Med       Date:  2022-08-18       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.